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sTo the editor 
We have read with interest the recent paper of Chen Y et al.,
about antibody prevalence among healthcare workers (HCWs)
exposed to COVID-19 1 . They found a significant incidence of
asymptomatic HCWs previously exposed to COVID-19 patients. We
have performed a cross-sectional descriptive study to assess the
clinical and epidemiological characteristics of mildly symptomatic
COVID-19 in a series of Spanish HCWs outpatients with reverse
transcription polymerase chain reaction (RT-PCR)-confirmed dis-
ease. Nowadays, Spain has the highest number of confirmed
cases of COVID-19 among its HCWs around the world. The study
protocol was approved by the clinical research ethics committee of
the Hospital Clinico San Carlos de Madrid and complied with the
clinical research guidelines of the Declaration of Helsinki. Criteria
for inclusion in our study were: age over 18 years, laboratory
(RT-PCR)-confirmed COVID-19; clinical cure (lack of symptoms
except olfactory and gustatory symptoms), healthcare worker
(both hospital and community care staff) and reading comprehen-
sion of Spanish. Exclusion criteria were hospitalization, symptom
persistence at the study outset or no laboratory confirmation of
COVID-19 infection. Clinical and epidemiological data was col-
lected though a voluntary, anonymous, self-administered online
questionnaire, accessible from Google Docs. The questionnaire
consisted of three general questions (about age, sex and occupa-
tion), two about general clinical issues (comorbidities and systemic
treatments), and two about COVID-19 symptoms. Questionnaire
data were transferred to an Excel database. Statistical analysis was
performed using the Statistical Package for the Social Sciences
for Windows (SPSS version 22,0; IBM Corp, Armonk, NY, USA).
Categorical variables are provided as counts and percentages and
continuous measurements as the mean, standard deviation (SD)
and range. We compared means for continuous variables through
independent group t tests. Proportions of categorical variables
were compared using the χ2 test. Significance was set at P < 0.05.
The final study population comprised 1177 patients fulfilling the
inclusion and exclusion criteria. Mean patient age was 41.7 (11.6)
years (range 19–68). There were 866 women (73.6%). There were
no differences in age according to gender ( p = 0.09). Most patients
were physicians (62.2%) or nurses (29%). 405 patients (34.4%) had
allergies (to pollens, dust mites, epithelia of animals, etc.). Most
frequent concomitant diseases were arterial hypertension (6.9%),
asthma (6.6%) and high blood cholesterol (5.7%). 
Fever at some time during the disease course was reported by
842 patients (71.5%) ( Table 1 ). Each patient described a mean of
7.88 (3.26) symptoms. https://doi.org/10.1016/j.jinf.2020.07.001 
0163-4453/© 2020 The British Infection Association. Published by Elsevier Ltd. All rights rSignificant differences emerged between both sexes in the fre-
uencies of most of the symptoms listed (15 of 21). 
In Table 2 we provide symptom frequencies by age group. 
So, while the symptoms most frequently reported were simi-
ar to those described in hospitalized patients (fatigue, fever and
ough) 2 , 3 , other symptoms appeared with greater frequency (myal-
ia, headache, nasal congestion, sore throat, diarrhea or chills).
n fact, in several studies regarding hospitalized patients, several
ymptoms that are common in outpatients with mild infection
ave been reported as infrequent 4 : myalgia (21.2–36.2%), headache
9.9–18.6%), nasal congestion (0.4–3.9%) or diarrhea (4.8–12.6%).
imilarly, other common symptoms in mildly symptomatic patients
een here and in other studies were not mentioned in hospital-
zed patients, even in the larger series 2 , 3 , like anosmia and ageusia,
hich have been reported with similar incidence to the present
tudy (71.6%) in a study among 202 mildly symptomatic outpa-
ients from Italy (64.4%). 5 Besides, in another recent study, anosmia
as strongly and independently associated with outpatient care in
 trial designed to identify risk factors for hospital admission, sug-
esting that this factor could be a marker of milder manifestations
f COVID-19. 6 The results of our study indicate that loss of smell
s even more frequent in mildly symptomatic patients under 40
ears of age. Rates of asymptomatic patients from 1.4% to 11.6%
f patients have been provided. 4 In our study, this rate was 1.9%,
hus, within the lower range of reported prevalence. However, the
urpose of our study was not to detect asymptomatic patients. Be-
ides, diagnostic tests for healthcare staff in the initial stages of the
pidemic in our country were practically restricted to symptomatic
ases, so these asymptomatic patients were HCWs in contact with
onfirmed COVID-19 cases who were tested because of epidemio-
ogical or occupational health risks (and have positive RT-PCR, un-
ike the HCWs in Chen Y at al ´s study). Finally, differences emerged
etween men and women in the presentation of most symptoms
just like Chen Y et al. study, 1 the proportion of females in our
tudy was high (73.6%) and may be attributed to the inclusion cri-
eria (HCWs, 70% of which in Spain are women)]. Some symptoms
ere also more frequent depending on patient age. 
Our study has several obvious limitations. First, data were
elf-reported, so recall biases are likely. However, our study was
onducted mid-pandemic and participants had just recovered. In
ddition, it was based on a cross-sectional survey, although only
ecovered patients with no active symptoms were included to
btain data for the whole disease course. The only exception was
hat we accepted patients with persisting olfactory and gustatory
lterations, because has been reported that 56% of patients show
ersistent olfactory dysfunction over the days following resolution
f the general clinical manifestations of COVID-19 7 . Finally, to
void possible infections, this was an online-based voluntary
tudy, so the possibility of selection bias exists. eserved. 
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Table 1 
Symptom frequencies: overall and by sex. 
SIGNS AND SYMPTOMS TOTAL ( n = 1177) (%) MEN ( n = 310) (%) WOMEN ( n = 866) (%) p 
Fever 842 (71.5) 241 (78.5) 600 (71.5) 0.018 
< 37.5 °C 192 (22.8) ∗ 34 (14.1) ∗ 158 (26.3) ∗
37.6–38 °C 393 (46.7) ∗ 105 (43.6) ∗ 287 (47.8) ∗ < 0.001 
38.1–39 °C 232 (27.6) ∗ 91 (37.8) ∗ 141 (23.5) ∗
> 39 °C 25 (3) ∗ 11 (4.6) ∗ 14 (2.3) ∗
Fatigue 878 (74.6) 216 (69.7) 662 (76.4) 0.02 
Cough 827 (70.3) 216 (69.7) 610 (70.4) 0.8 
Myalgia 822 (69.8) 223 (71.9) 599 (69.2) 0.36 
Headache 814 (69.2) 186 (60.0) 628 (72.5) < 0.001 
Anosmia 625 (53.1) 130 (41.9) 495 (57.2) < 0.001 
Nasal congestion 570 (48.4) 117 (37.7) 453 (52.3) < 0.001 
Sore throat 552 (46.9) 115 (37.1) 436 (50.3) < 0.001 
Diarrhea 511 (43.4) 111 (35.8) 399 (46.1) 0.002 
Chills 509 (43.2) 129 (41.6) 380 (43.9) 0.49 
Ageusia 405 (34.4) 78 (25.2) 327 (37.8) < 0.001 
Dysgeusia 380 (32.3) 106 (34.2) 274 (31.6) 0.41 
Nausea 243 (20.6) 29 (9.4) 214 (24.7) < 0.001 
Stabbing chest pain 240 (20.4) 44 (14.2) 196 (22.6) 0.002 
Shortness of breath 218 (18.5) 38 (12.3) 180 (20.8) 0.001 
Hyposmia 200 (17) 59 (19) 141 (16.3) 0.27 
Abdominal pain 167 (14.2) 25 (8.1) 142 (16.4) < 0.001 
Conjunctivitis 104 (8.8) 21 (6.8) 82 (9.5) 0.15 
Dizziness 86 (7.3) 9 (2.9) 77 (8.9) 0.001 
Mouth and tongue sores 79 (6.7) 12 (3.9) 67 (7.7) 0.02 
Vomiting 55 (4.7) 5 (1.6) 50 (5.8) 0.003 
Skin rash 15 (1.3) 2 (0.6) 13 (1.5) 0.25 
Asymptomatic 23 (1.9) 10 (3.2) 13 (1.5) 0.06 
( ∗ among patients with fever). 
Table 2 
Symptom frequencies: overall and by age group. 
SIGNS AND SYMPTOMS TOTAL ( n = 1177) 
(%) 
< 30 years 
( n = 278) (%) 
31–40 years 
( n = 285) (%) 
41–50 years 
( n = 296) (%) 
51–60 years 
( n = 246) (%) 
> 60 years ( n = 72) 
(%) 
p 
Fever < 37.5 °C 
37.6–38 °C 38.1–39 °C 
> 39 °C 
842 (71.5) 192 
(22.8) ∗ 393 (46.7) ∗
232 (27.6) ∗ 25 (3) ∗
168 (62.9) 35 
(20.8) ∗ 83 (49.4) ∗
46 (27.4) ∗ 4 (2.4) ∗
212 (76.5) 50 
(23.6) ∗ 97 (45.8) ∗
58 (27.4) ∗ 7 (3.3) ∗
228 (78.1) 59 
(25.9) ∗ 102 (44.7) ∗
58 (25.4) ∗ 9 (3.9) ∗
176 (73) 33 (18.8) ∗
85 (48.3) ∗ 53 
(30.1) ∗ 5 (2.8) ∗
58 (82.9) 15 
(25.9) ∗ 26 (44.8) ∗
17 (29.3) ∗ 0 
< 0.001 0.86 
Fatigue 878 (74.6) 196 (70.5) 214 (75.1) 227 (76.7) 188 (76.4) 53 (73.6) 0.46 
Cough 827 (70.3) 177 (63.7) 207 (72.6) 216 (73) 174 (70.7) 53 (73.6) 0.09 
Myalgia 822 (69.8) 180 (64.7) 186 (65.3) 220 (74.3) 186 (75.6) 50 (69.4) 0.01 
Headache 814 (69.2) 201 (72.3) 209 (73.3) 215 (72.6) 147 (59.8) 42 (58.3) 0.001 
Anosmia 625 (53.1) 163 (58.6) 179 (62.8) 148 (50) 105 (42.7) 30 (41.7) < 0.001 
Nasal congestion 570 (48.4) 158 (56.8) 160 (56.1) 130 (43.9) 96 (39) 26 (36.1) < 0.001 
Sore throat 552 (46.9) 123 (44.2) 145 (50.9) 148 (50) 105 (42.7) 31 (43.1) 0.21 
Diarrhea 511 (43.4) 107 (38.5) 126 (44.2) 131 (44.3) 115 (46.7) 32 (44.4) 0.4 
Chills 509 (43.2) 93 (33.5) 117 (41.1) 154 (52) 111 (45.1) 34 (47.2) < 0.001 
Ageusia 405 (34.4) 121 (43.5) 110 (38.6) 95 (32.1) 62 (25.2) 17 (23.6) < 0.001 
Dysgeusia 380 (32.3) 76 (27.3) 94 (33) 98 (33.1) 89 (36.2) 23 (31.9) 0.29 
Nausea 243 (20.6) 29 (9.4) 62 (21.8) 61 (20.6) 53 (21.5) 11 (15.3) 0.8 
Stabbing chest pain 240 (20.4) 51 (18.3) 58 (20.4) 73 (24.7) 47 (19.1) 11 (15.3) 0.24 
Shortness of breath 218 (18.5) 50 (18) 54 (18.9) 55 (18.6) 47 (19.1) 12 (16.7) 0.99 
Hyposmia 200 (17) 45 (16.2) 41 (14.4) 45 (15.2) 54 (22) 15 (20.8) 0.13 
Abdominal pain 167 (14.2) 32 (11.5) 39 (12.7) 45 (15.2) 41 (16.7) 10 (13.9) 0.53 
Conjunctivitis 104 (8.8) 24 (8.6) 18 (6.3) 31 (10.5) 23 (9.3) 8 (11.1) 0.44 
Dizziness 86 (7.3) 34 (12.2) 17 (6) 16 (5.4) 14 (5.7) 5 (6.9) 0.01 
Mouth and tongue 
sores 
79 (6.7) 24 (8.6) 28 (9.8) 15 (5.1) 6 (2.4) 6 (8.3) 0.005 
Vomiting 55 (4.7) 11 (4) 12 (4.2) 15 (5.1) 17 (6.9) 0 0.14 
Skin rash 15 (1.3) 4 (1.4) 4 (1.4) 4 (1.4) 1 (0.4) 2 (2.8) 0.58 
Asymptomatic 23 (1.9) 8 (2.9) 3 (1.1) 4 (1.4) 5 (2) 3 (4.2) 0.3 
( ∗ among patients with fever). 
 
c  
p  
m  
a
R
1  
 
 
2  
3  
 
 
4  
 
 
5  
 To the best of our knowledge, this is the largest described clini-
al case series of mildly symptomatic HCWs COVID-19 disease out-
atients. Their particular clinical spectrum could help physicians
ake a correct diagnosis and thus help avoid infection spread, as
 health priority in most countries. 
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